Suppr超能文献

乌头碱诱导清醒大鼠死亡的抑制作用:抗心律失常药物的筛选试验。

Inhibition of aconitine-induced mortality in the conscious rat: a screening test for antiarrhythmic drugs.

作者信息

Gutiérrez B, Vilumara A, Farré A J

出版信息

Methods Find Exp Clin Pharmacol. 1987 May;9(5):307-10.

PMID:2886712
Abstract

A test for inhibition of mortality induced by intravenous injection of aconitine in rats is proposed as a particularly valid method, owing to its simplicity and degree of specificity, for inclusion among the preliminary screening tests for antiarrhythmic activity. LD50 (63.5 micrograms/kg, i.v.) and LD99 (118.9 micrograms/kg, i.v.) values of aconitine were determined. The dose employed for screening was 100 micrograms/kg i.v., which in control animals produced a death rate of 97.7% (293 deaths/300 treated animals). The protection produced by various drugs belonging to different groups of antiarrhythmics was studied. ED50s, expressed in mg/kg i.p., were as follows: Class I antiarrhythmics: flecainide, 5.5; E-4017, 30.0; lorcainide, 30.9; quinidine, 41.1; diphenylhydantoin, 42.3; lidocaine, 48.5; ajmaline: 53.9; procainamide, 61.3. Class II antiarrhythmics: pindolol 22.8; propranolol, 24.9; oxprenolol, 38.0; labetalol, 60.7; atenolol, 100.0; metoprolol, approximately 160; acebutalol, greater than 160; timolol, greater than 160. Class III antiarrhythmics: amiodarone, greater than 160. Class IV antiarrhythmics: verapamil, diltiazem and nifedipine were inactive up to 40 mg/kg. The test would appear to be selective for membrane-stabilizing agents (class I) and beta-blockers (class II), but in view of the magnitudes of activity found, it should be used in combination with other antiarrhythmic tests.

摘要

由于其简单性和特异性程度,一种用于抑制大鼠静脉注射乌头碱所致死亡率的试验被提议作为一种特别有效的方法,用于纳入抗心律失常活性的初步筛选试验中。测定了乌头碱的半数致死量(LD50,静脉注射63.5微克/千克)和99%致死量(LD99,静脉注射118.9微克/千克)。筛选所用剂量为静脉注射100微克/千克,在对照动物中产生的死亡率为97.7%(293只死亡/300只处理动物)。研究了不同组抗心律失常药物产生的保护作用。以毫克/千克腹腔注射表示的半数有效量(ED50)如下:I类抗心律失常药物:氟卡尼,5.5;E - 4017,30.0;劳卡尼,30.9;奎尼丁,41.1;苯妥英钠,42.3;利多卡因,48.5;阿义马林,53.9;普鲁卡因胺,61.3。II类抗心律失常药物:吲哚洛尔,22.8;普萘洛尔,24.9;氧烯洛尔,38.0;拉贝洛尔,60.7;阿替洛尔,100.0;美托洛尔,约160;醋丁洛尔,大于160;噻吗洛尔,大于160。III类抗心律失常药物:胺碘酮,大于160。IV类抗心律失常药物:维拉帕米、地尔硫䓬和硝苯地平在高达40毫克/千克时无活性。该试验似乎对膜稳定剂(I类)和β受体阻滞剂(II类)具有选择性,但鉴于所发现的活性大小,应与其他抗心律失常试验联合使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验